Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00369109 · ClinicalTrials.gov registry record

Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors

A clinical trial, sponsored by Barbara Ann Karmanos Cancer Institute.

Completed
Registry status
60
Enrollment target

NCT00369109 is a clinical trial that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 60 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00369109 has completed, sponsored by Barbara Ann Karmanos Cancer Institute.

COMPLETED
Registry status
60 participants
Enrollment target

Study Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This laboratory study is collecting skin biopsy specimens from patients receiving irinotecan or gemcitabine for advanced solid tumors and using them to study change in DNA due to this treatment.

Interventions

  • OTHER biologic sample preservation procedure
  • OTHER laboratory biomarker analysis
  • PROCEDURE biopsy
  • OTHER immunohistochemistry staining method

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2006-02
Est. Completion 2007-06

What the Registry Record Tells You About NCT00369109

The ClinicalTrials.gov registry entry for NCT00369109 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which biologic sample preservation procedure is the first listed.

NCT00369109 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00369109 about?

NCT00369109 is a clinical study titled "Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors". RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This laboratory study is collecting skin biopsy specimens from patients receiving irinotecan or gemcitabine for advanced soli...

What is the current status of trial NCT00369109?

This trial is currently completed. The enrollment target is 60 participants. The study started on 2006-02. Estimated completion is 2007-06.

What interventions are being tested in trial NCT00369109?

The interventions under investigation include: biologic sample preservation procedure (OTHER), laboratory biomarker analysis (OTHER), biopsy (PROCEDURE), immunohistochemistry staining method (OTHER).

Who is sponsoring clinical trial NCT00369109?

This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.